Synapse Open Synapse
Biology

B7-H4‒directed antibody-drug conjugate AZD8205 (puxitatug samrotecan) in patients with advanced/metastatic solid tumors: the Phase 1/2a (BLUESTAR), first-in-human study

Nature Communications · · 1 min read

B7-H4 is a promising therapeutic target in solid tumors because of its frequent expression in cancer cells, limited normal tissue distribution, and immunosuppressive functions.

Latest from Nature Communications